Source / episode info
- **Episode:**395
- **Title:**Divine Intervention Episode 395 – The Clutch Diabetes Management Podcast
- **Published:**2022-06-08
- Source:Episode page
One-liner
This episode provides a comprehensive review of diabetes management strategies, covering insulin dosing protocols, the mechanisms, indications, and critical contraindications/side effects for major anti-diabetic drug classes including biguanides (Metformin), sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, and TZDs.
High-yield summary
- Insulin Dosing: Initial insulin requirement is typically 0.5 units/kg total daily dose, split 50% basal (long-acting: glargine, detemir) and 50% mealtime (divided by number of meals).
- Metformin (Biguanide): Decreases hepatic gluconeogenesis; contraindicated in CKD and acute metabolic stress (e.g., surgery/trauma) due to risk of lactic acidosis. Does not cause hypoglycemia.
- SGLT2 Inhibitors: Block glucose reabsorption in the proximal convoluted tubule, leading to glucosuria; key benefits include improved survival in heart failure. Contraindicated in severe renal impairment.
- TZDs (Thiazolidinediones): Act as PPAR- agonists; cause fluid retention and weight gain; contraindicated in patients with heart failure due to risk of exacerbating volume overload.
- GLP-1/DPP-4 Inhibitors: Both classes stimulate insulin release and decrease glucagon; associated with a risk of pancreatitis and MTC, making caution necessary in these high-risk populations.
Learning objectives
- Differentiate the mechanisms of action for major anti-diabetic drug classes (e.g., biguanides vs SGLT2 inhibitors vs GLP-1 agonists).
- Calculate appropriate initial total daily insulin requirements based on body weight and basal/bolus ratios.
- Identify critical contraindications for specific agents, particularly in the context of renal impairment, heart failure, or malignancy risk (MTC).
- Understand the metabolic consequences of different drug classes (e.g., lactic acidosis with Metformin; fluid retention with TZDs).
- Recognize that T2DM progression can necessitate insulin therapy due to pancreatic burnout or chronic pancreatitis.
Board exam buzzwords